← Leaderboards
Christina L Nance
Baylor College Of Medicine
$1,139,037
Attributed
$1,139,037
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $248.3K · FY2005–11$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$1,139,037 · 2
By mechanism
R21$1,139,037 · 2
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Elizabeth Chiao$12,842,422
- William Thomas Shearer$34,592,326
- Andrew P Rice$15,689,795
- Helen E Heslop$25,308,937
- Farook Jahoor$8,036,031
Others in their field
Top investigators on “Developing Countries”
- David R. Weir · University Of Michigan At Ann Arbor$321,165,185
- Lawrence Corey · Fred Hutchinson Cancer Center$291,089,775
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$289,810,358
- James Dennis Neaton · Northwestern University$203,539,316
- Michelle Vargas · Ppd Development Lp$176,419,297
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
Research focus
Developing CountriesAcquired Immunodeficiency SyndromeAffinityAdultAdverse EventAntiretroviral TherapyAntiviral AgentsBaseAnti-Hiv AgentsBinding SitesBiological FactorsAnti-Retroviral AgentsCapsule (Pharmacologic)Cd4 AntigensCd4 Positive T LymphocytesCellsChildClinical ResearchClinical TrialsBinding (Molecular Function)CohortComplementary And Alternative MedicineContainmentDosage
Grant awards (7)
Phase I Study to Evaluate Safety and Toxicity of EGCG in HIV-1-Infected Subjects$119,925
R21 · FY2011 · AT · contact PI
Phase I Study to Evaluate Safety and Toxicity of EGCG in HIV-1-Infected Subjects$187,964
R21 · FY2010 · AT · contact PI
Phase I Study to Evaluate Safety and Toxicity of EGCG in HIV-1-Infected Subjects$230,779
R21 · FY2009 · AT · contact PI
Phase I Study to Evaluate Safety and Toxicity of EGCG in HIV-1-Infected Subjects$17,560
R21 · FY2009 · AT · contact PI
Phase I Study to Evaluate Safety and Toxicity of EGCG in HIV-1-Infected Subjects$212,215
R21 · FY2008 · AT · contact PI
Binding of Epigallocatechin Gallate to CD4$183,094
R21 · FY2006 · AT · contact PI
Binding of Epigallocatechin Gallate to CD4$187,500
R21 · FY2005 · AT